We present a case oferythromelalgia in a 68 year old lady who responded, within 48 hours, to a twice daily topical application of capsaicin cream 0.025%. Capsaicin cream was stopped after 2 months, and 6 months later the patient continued to have the symptomatic relief she experienced initially.
Introduction
Erythromelalgia is a rare syndrome characterized by pain, redness and increased skin temperature of one or more extremities. It was first described by Mitchell in 1878.1 Symptoms are characteristically exacerbated by dependency or heat exposure, and relieved by elevation or cooling of the affected limb.2'3 Capsaicin is a new topical medication for neuralgia. It is thought that capsaicin accentuates the release of substance P from sensory nerve fibres and after repeated applications depletes the neurones of substance P, which is an important mediator of nociceptive impulses.'3"'4 It is not clear what the underlying mechanism of pain in erythromelalgia is, but it is possible that substance P is involved. We report an intractable case of erythromelalgia and its successful response to capsaicin cream.
Case report
A 68 year old woman presented with a 10-month history of severe burning pain in the anterior surface of both lower legs and feet. Her symptoms started 3 months after she had had a lumbar spinal fusion operation. She developed tingling in the feet, which spread to involve the legs associated with burning pain, redness and foot swelling. She described hyperaesthesiae to light stimuli, although she was able to tolerate firmer handling. The pain was predominantly worse when walking leading to total immobility.
On examination there was intense erythema of both lower legs and feet, which did not blanch on pressure, and turned a purplish hue when dependent. Her feet were warm and peripheral pulses were full. Straight leg raising was limited to about 450 by back discomfort, although movement of her lower limb joints was reasonable. Erythromelalgia was diagnosed and aspirin 75 mg daily and propranolol 80 mg twice daily were commenced. Two months later, no appreciable symptomatic relief was observed. In addition, mild cardiac failure was precipitated by the beta blocker.
Extensive laboratory investigations were performed at presentation. Full blood count, erythrocyte sedimentation rate, urea, creatinine and electrolytes, liver function tests and thyroid function tests were all normal. Autoimmune profile and rheumatoid factor were negative. Protein electrophoresis and immunoglobulin levels were normal.
Capsaicin cream 0.025% was applied topically to a small area in the right lower leg, and an inert cream (E-45) was applied to the left lower leg as a control. This was to identify any atopic reaction to capsaicin and to illustrate the beneficial effect of capsaicin after taking into account the cooling effect of cream. These applications were repeated 12 hourly. Within 48 hours, there was a marked decrease in the local skin temperature, erythema and local pain in the treated area of 1O cm in diameter in the right leg compared to the left. Application of the capsaicin cream was then extended to inyolve the whole of the erythematous areas in both legs. This continued to achieve improvement in symptoms and the degree of erythema. Figure 1 shows the legs before and 2 weeks after treatment with capsaicin cream. Capsaicin cream was stopped after 2 months and 6 months later the patient continued to have the symptomatic relief she experienced initially.
Comment
Erythromelalgia is characterized by burning discomfort, warmth and dermal erythema of the extremities, exacerbation of symptoms by depen-a b Figure 1 The degree of erythema in the lower limbs before (a) and 2 Treatment principally is that of the underlying systemic condition in those with secondary erythromelalgia but this is not always possible. However, the majority of patients with erythromelalgia do seem to respond to aspirin.2'3 Treatment may be difficult if aspirin has failed and a variety of medications have been tried in those circumstances, for example: indomethacin,3 propranolol8 and methysergide.9
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is a new topical medication for neuralgia. It has been used to treat post-herpetic neuralgia'0 and painful diabetic peripheral neuropathy" among other painful conditions without the adverse effects associated with systemic medications. In this article we report successful symptomatic relief in erythromelalgia with topical capsaicin, which has to our knowledge never been tried before in this condition. The sensory neurones with unmyelinated C-fibres have been implicated in mediating cutaneous pain. These neurones possess a unique sensitivity to capsaicin, the lipophilicity of which enhances its dissolution and contributes to its action on sensory neurone membranes.'2 It is thought that capsaicin accentuates the release of substance P from sensory nerve fibres and, after repeated applications, depletes the neurones of substance P, and hence tachyphylaxis occurs.'0 Substance P has been shown to be important, if not the essential chemomediators of nociceptive impulses from the periphery to the central nervous system.'3"4 The effective outcome of capsaicin in this case of erythromelalgia suggests that the symptoms of burning discomfort, warmth and dermal erythema of the extremities are largely mediated by substance P. The continued symptomatic relief observed 6 months after cessation of the use ofcapsaicin cream suggests some changes in the nerve conduction of a damaged peripheral nerve with or without its central connection. 
